Jpmorgan Chase & CO Celularity Inc Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$0.17 - $0.33 $27 - $53	161 New	161 $0
Q2 2023 Aug 11, 2023	SELL	$0.42 - $0.81 $20,425 - $39,391	-48,631 Reduced 99.67%	161 $0
Q1 2023 May 18, 2023	BUY	$0.56 - $1.15 $27,233 - $55,925	48,631 Added 30205.59%	48,792 $30,000
Q1 2023 May 11, 2023	SELL	$0.56 - $1.15 $20,192 - $41,466	-36,058 Reduced 99.56%	161 $0
Q4 2022 Feb 13, 2023	SELL	$1.08 - $2.35 $455 - $991	-422 Reduced 1.15%	36,219 $46,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $4.31 $12,120 - $121,485	28,187 Added 333.42%	36,641 $84,000
Q2 2022 Aug 11, 2022	BUY	$2.81 - $12.91 $23,755 - $109,141	8,454 New	8,454 $28,000

23.6M

Ticker CELU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,424,000
Market Cap $319M
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.